Publication at First Faculty of Medicine |
2018
Abstract
Ustekinumab is a fully human monoclonal antibody IgG1 blocking the proinflammatory pathways of interleukins 12 and 23. In the end of the year 2016, it was approved by regulatory agencies for further biological therapy of Crohn's disease.
Since the beginning of February 2018, indication criteria for coverage of this treatment in the Czech Republic are defined, making this therapy more widely available to Czech patients with Crohn's disease. Trials published to date demonstrate a significant anti-inflammatory effect of ustekinumab therapy.
Thus, making this drug available to our patients makes it possible for many to hope that their unsatisfactory health state would eventually improve.